Xeris Pharmaceuticals Inc.
shares rallied in the extended session Monday after the drug maker said its diabetes treatment showed positive results in a mid-stage clinical study. Xeris shares surged 23% after hours, following a 4.6% decline in the regular session to close at $5.79. The company said a Phase 2 study showed that its ready-to-use glucagon "was adequate" to maintain normal blood sugar levels in Type 1 diabetes patients during and after moderate-to-high intensity aerobic exercise versus standard care.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: